PBK/TOPK overexpression and survival in solid tumors: A PRISMA-compliant meta-analysis

BACKGROUND: The prognostic significance of PBK/TOPK overexpression in solid tumors remains controversial. Therefore, we carried out a meta-analysis to evaluate the impact of PBK/TOPK overexpression in solid tumors on patients’ overall survival (OS) and disease-free survival (DFS). METHODS: Relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ming, Xu, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417550/
https://www.ncbi.nlm.nih.gov/pubmed/30855480
http://dx.doi.org/10.1097/MD.0000000000014766
Descripción
Sumario:BACKGROUND: The prognostic significance of PBK/TOPK overexpression in solid tumors remains controversial. Therefore, we carried out a meta-analysis to evaluate the impact of PBK/TOPK overexpression in solid tumors on patients’ overall survival (OS) and disease-free survival (DFS). METHODS: Relevant articles were identified through searching the PubMed, Embase and Web of Science up to May 2017. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the effects. RESULTS: In this meta-analysis, 12 studies involving 1571 participants were included, PBK/TOPK overexpression was significantly associated with poor OS (pooled HR = 1.91, 95%CI = 1.22-3.00, P = .005) and short DFS (pooled HR = 1.95, 95%CI = 1.46-2.58, P < .001). CONCLUSIONS: PBK/TOPK overexpression was associated with poor survival in human solid tumors which may be a valuable prognosis biomarker and a potential therapeutic target of solid tumors.

Ejemplares similares